Logo image of CHSCN

CHS INC - CHSINC 7.1 PERP (CHSCN) Stock Fundamental Analysis

NASDAQ:CHSCN - Nasdaq - US12542R5063

25.722  -0.16 (-0.61%)

Fundamental Rating

4

Overall CHSCN gets a fundamental rating of 4 out of 10. We evaluated CHSCN against 91 industry peers in the Food Products industry. CHSCN has only an average score on both its financial health and profitability. CHSCN is valued expensive and it does not seem to be growing. Finally CHSCN also has an excellent dividend rating. This makes CHSCN very considerable for dividend investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

CHSCN had a positive operating cash flow in the past year.
In the past 5 years CHSCN has always been profitable.
CHSCN had a positive operating cash flow in each of the past 5 years.
CHSCN Yearly Net Income VS EBIT VS OCF VS FCFCHSCN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1B 2B 3B

1.2 Ratios

CHSCN has a Return On Assets of 7.92%. This is amongst the best in the industry. CHSCN outperforms 83.72% of its industry peers.
Looking at the Return On Equity, with a value of 14.11%, CHSCN is in the better half of the industry, outperforming 74.42% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 5.88%, CHSCN is in line with its industry, outperforming 59.30% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for CHSCN is below the industry average of 9.02%.
The 3 year average ROIC (5.40%) for CHSCN is below the current ROIC(5.88%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.92%
ROE 14.11%
ROIC 5.88%
ROA(3y)7.36%
ROA(5y)5.96%
ROE(3y)14.03%
ROE(5y)11.3%
ROIC(3y)5.4%
ROIC(5y)4.37%
CHSCN Yearly ROA, ROE, ROICCHSCN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 5 10 15

1.3 Margins

Looking at the Profit Margin, with a value of 3.62%, CHSCN is in line with its industry, outperforming 54.65% of the companies in the same industry.
CHSCN's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 2.42%, CHSCN is in line with its industry, outperforming 40.70% of the companies in the same industry.
In the last couple of years the Operating Margin of CHSCN has grown nicely.
The Gross Margin of CHSCN (5.06%) is worse than 83.72% of its industry peers.
In the last couple of years the Gross Margin of CHSCN has grown nicely.
Industry RankSector Rank
OM 2.42%
PM (TTM) 3.62%
GM 5.06%
OM growth 3Y44.42%
OM growth 5Y18.46%
PM growth 3Y41.04%
PM growth 5Y11.91%
GM growth 3Y14.66%
GM growth 5Y9.3%
CHSCN Yearly Profit, Operating, Gross MarginsCHSCN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 1 2 3 4 5

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CHSCN is still creating some value.
Compared to 1 year ago, CHSCN has an improved debt to assets ratio.
CHSCN Yearly Shares OutstandingCHSCN Yearly Shares OutstandingYearly Shares Outstanding 2018 2M 4M 6M 8M 10M
CHSCN Yearly Total Debt VS Total AssetsCHSCN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5B 10B 15B

2.2 Solvency

CHSCN has an Altman-Z score of 2.82. This is not the best score and indicates that CHSCN is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.82, CHSCN is in the better half of the industry, outperforming 62.79% of the companies in the same industry.
CHSCN has a debt to FCF ratio of 1.02. This is a very positive value and a sign of high solvency as it would only need 1.02 years to pay back of all of its debts.
CHSCN has a better Debt to FCF ratio (1.02) than 84.88% of its industry peers.
CHSCN has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
CHSCN has a Debt to Equity ratio of 0.19. This is in the better half of the industry: CHSCN outperforms 67.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 1.02
Altman-Z 2.82
ROIC/WACC1.02
WACC5.79%
CHSCN Yearly LT Debt VS Equity VS FCFCHSCN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2B 4B 6B 8B 10B

2.3 Liquidity

CHSCN has a Current Ratio of 1.58. This is a normal value and indicates that CHSCN is financially healthy and should not expect problems in meeting its short term obligations.
CHSCN has a Current ratio of 1.58. This is comparable to the rest of the industry: CHSCN outperforms 52.33% of its industry peers.
A Quick Ratio of 0.91 indicates that CHSCN may have some problems paying its short term obligations.
CHSCN has a Quick ratio (0.91) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 0.91
CHSCN Yearly Current Assets VS Current LiabilitesCHSCN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B 8B

1

3. Growth

3.1 Past

Looking at the last year, CHSCN shows a very negative growth in Revenue. The Revenue has decreased by -17.09% in the last year.
The Revenue has been growing slightly by 6.88% on average over the past years.
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-17.09%
Revenue growth 3Y17.08%
Revenue growth 5Y6.88%
Sales Q2Q%-19.63%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CHSCN Yearly Revenue VS EstimatesCHSCN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 10B 20B 30B 40B
CHSCN Yearly EPS VS EstimatesCHSCN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

3

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
CHSCN Price Earnings VS Forward Price EarningsCHSCN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

96.51% of the companies in the same industry are more expensive than CHSCN, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, CHSCN is valued cheaply inside the industry as 98.84% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 0.14
EV/EBITDA 0.96
CHSCN Per share dataCHSCN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1K 2K 3K

4.3 Compensation for Growth

The decent profitability rating of CHSCN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

8

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 7.00%, CHSCN is a good candidate for dividend investing.
CHSCN's Dividend Yield is rather good when compared to the industry average which is at 3.86. CHSCN pays more dividend than 94.19% of the companies in the same industry.
CHSCN's Dividend Yield is rather good when compared to the S&P500 average which is at 2.28.
Industry RankSector Rank
Dividend Yield 7%

5.2 History

The dividend of CHSCN has a limited annual growth rate of 0.78%.
CHSCN has paid a dividend for at least 10 years, which is a reliable track record.
CHSCN has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)0.78%
Div Incr Years0
Div Non Decr Years10
CHSCN Yearly Dividends per shareCHSCN Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0.5 1 1.5

5.3 Sustainability

11.11% of the earnings are spent on dividend by CHSCN. This is a low number and sustainable payout ratio.
DP11.11%
EPS Next 2YN/A
EPS Next 3YN/A
CHSCN Yearly Income VS Free CF VS DividendCHSCN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1B 2B
CHSCN Dividend Payout.CHSCN Dividend Payout, showing the Payout Ratio.CHSCN Dividend Payout.PayoutRetained Earnings

CHS INC - CHSINC 7.1 PERP

NASDAQ:CHSCN (1/22/2025, 11:30:27 AM)

25.722

-0.16 (-0.61%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)01-08 2025-01-08
Earnings (Next)04-01 2025-04-01
Inst Owners13.8%
Inst Owner Change0%
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap315.61M
Analysts0
Price TargetN/A
Short Float %0.08%
Short Ratio0.41
Dividend
Industry RankSector Rank
Dividend Yield 7%
Yearly Dividend2.04
Dividend Growth(5Y)0.78%
DP11.11%
Div Incr Years0
Div Non Decr Years10
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.01
P/FCF 0.14
P/OCF 0.11
P/B 0.03
P/tB 0.03
EV/EBITDA 0.96
EPS(TTM)N/A
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)178.98
FCFY695.83%
OCF(TTM)233.94
OCFY909.48%
SpS3422.59
BVpS877.08
TBVpS877.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.92%
ROE 14.11%
ROCE 7.68%
ROIC 5.88%
ROICexc 6.17%
ROICexgc 6.17%
OM 2.42%
PM (TTM) 3.62%
GM 5.06%
FCFM 5.23%
ROA(3y)7.36%
ROA(5y)5.96%
ROE(3y)14.03%
ROE(5y)11.3%
ROIC(3y)5.4%
ROIC(5y)4.37%
ROICexc(3y)5.96%
ROICexc(5y)4.73%
ROICexgc(3y)6.08%
ROICexgc(5y)4.81%
ROCE(3y)7.21%
ROCE(5y)6.02%
ROICexcg growth 3Y73.02%
ROICexcg growth 5Y27.66%
ROICexc growth 3Y72.21%
ROICexc growth 5Y27.52%
OM growth 3Y44.42%
OM growth 5Y18.46%
PM growth 3Y41.04%
PM growth 5Y11.91%
GM growth 3Y14.66%
GM growth 5Y9.3%
F-Score6
Asset Turnover2.19
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 1.02
Debt/EBITDA 1.33
Cap/Depr 122.19%
Cap/Sales 1.61%
Interest Coverage 250
Cash Conversion 182.9%
Profit Quality 144.65%
Current Ratio 1.58
Quick Ratio 0.91
Altman-Z 2.82
F-Score6
WACC5.79%
ROIC/WACC1.02
Cap/Depr(3y)76.68%
Cap/Depr(5y)79.95%
Cap/Sales(3y)0.94%
Cap/Sales(5y)1.13%
Profit Quality(3y)105.8%
Profit Quality(5y)111.96%
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-17.09%
Revenue growth 3Y17.08%
Revenue growth 5Y6.88%
Sales Q2Q%-19.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-35.39%
EBIT growth 3Y69.09%
EBIT growth 5Y26.62%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y620.74%
FCF growth 3Y59.62%
FCF growth 5Y30.48%
OCF growth 1Y387.5%
OCF growth 3Y44.56%
OCF growth 5Y25.04%